You can buy or sell CorMedix and other stocks, options, ETFs, and crypto commission-free!
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Read More The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
Berkeley Heights, New Jersey
52 Week High
52 Week Low
Seeking AlphaMay 13
CorMedix, Inc. CEO Khoso Baluch on Q1 2019 Results - Earnings Call Transcript
CorMedix, Inc. (NYSEMKT:CRMD) Q1 2019 Results Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Dan Ferry - IR-LifeSci Advisors Khoso Baluch - CEO Bob Cook - CFO Phoebe Mounts - EVP and General Counsel Paul Chew - Chief Medical Officer Conference Call Participants Operator Greetings. Welcome to CorMedix's First Quarter 2019 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded. I would now like to turn the conference over to your host M...
Yahoo FinanceMay 13
CorMedix Reports Q1 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 13
CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business events. Recent Corporate and Clinical Highlights: Announced that the...
-$0.28 per share
-$0.22 per share